OTCMKTS:SDMHF Sartorius Stedim Biotech (SDMHF) Stock Price, News & Analysis $205.68 0.00 (0.00%) As of 08/15/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesShort InterestBuy This Stock About Sartorius Stedim Biotech Stock (OTCMKTS:SDMHF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SDMHF alerts:Sign Up Key Stats Today's Range$205.68▼$205.6850-Day Range$191.25▼$245.2052-Week Range$170.00▼$245.20Volume1,163 shsAverage Volume2,262 shsMarket CapitalizationN/AP/E Ratio47.72Dividend Yield0.58%Price TargetN/AConsensus RatingHold Company Overview Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG. Read More Sartorius Stedim Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreSDMHF MarketRank™: Sartorius Stedim Biotech scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Sartorius Stedim Biotech.Read more about Sartorius Stedim Biotech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sartorius Stedim Biotech is 47.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Sartorius Stedim Biotech is 47.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.90.Read more about Sartorius Stedim Biotech's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverSartorius Stedim Biotech has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Sartorius Stedim Biotech has recently decreased by 64.25%, indicating that investor sentiment is improving significantly. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldSartorius Stedim Biotech has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthSartorius Stedim Biotech does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Sartorius Stedim Biotech is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Sartorius Stedim Biotech's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverSartorius Stedim Biotech has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Sartorius Stedim Biotech has recently decreased by 64.25%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.48 News SentimentSartorius Stedim Biotech has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sartorius Stedim Biotech this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sartorius Stedim Biotech insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 9.21% of the stock of Sartorius Stedim Biotech is held by institutions.Read more about Sartorius Stedim Biotech's insider trading history. Receive SDMHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address SDMHF Stock News HeadlinesSartorius to invest $3m for minority share in biotech start-up NanoteinAugust 12, 2025 | msn.comSartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy ManufacturingAugust 11, 2025 | businesswire.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 18 at 2:00 AM | Brownstone Research (Ad)Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in AfricaJuly 29, 2025 | globenewswire.comSartorius Stedim Biotech S.A. (SDMHF) - Yahoo FinanceJune 27, 2025 | au.finance.yahoo.comKepler Capital Reaffirms Their Hold Rating on Sartorius Stedim Biotech (0RG8)April 26, 2025 | markets.businessinsider.comEarnings call transcript: Sartorius Stedim Biotech beats Q1 2025 expectationsApril 18, 2025 | uk.investing.comResolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.March 25, 2025 | markets.businessinsider.comSee More Headlines SDMHF Stock Analysis - Frequently Asked Questions How have SDMHF shares performed this year? Sartorius Stedim Biotech's stock was trading at $195.00 at the beginning of 2025. Since then, SDMHF stock has increased by 5.5% and is now trading at $205.6759. How do I buy shares of Sartorius Stedim Biotech? Shares of SDMHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/18/2025Next Earnings (Estimated)10/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolOTCMKTS:SDMHF CIKN/A Webwww.sartorius.com Phone(344) 284-5600FaxN/AEmployees10,382Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio47.72 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:SDMHF) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sartorius Stedim Biotech S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sartorius Stedim Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.